This article is more than 5 years old. Information may no longer be current.

VIDEO: CMV in hematopoietic cell transplantation requires new treatments

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW ORLEANS — Genovefa Papanicolaou, MD, an infectious disease specialist affiliated with Memorial Sloan Kettering Cancer Center in New York, discusses the significant problem of cytomegalovirus, or CMV, in hematopoietic cell transplantation patients.

Better drugs with fewer side effects are needed to both treat and prevent CMV, Papanicolaou says. Merck’s investigational antiviral drug letermovir was highly effective in a recent phase 3 trial at preventing infection with CMV in patients who underwent allogeneic hematopoietic cell transplantation.

Disclosure: Papanicolaou has received research funding from Merck and consultant and research funding from Astellas and Chimerix.